Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Completed 3

Sponsor Class

OTHER_GOV 1OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 7Sarcoma 3Head & Neck 2CNS 2Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Sarcoma, Kaposi 3Acquired Immunodeficiency Syndrome 2Multi-centric Castleman's Disease 1Immune Reconstitution Inflammatory Syndrome 1Castleman Disease 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Valganciclovir × Sarcoma × Clear all
NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed
40 enrolled 6 charts
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

NCT00194467 2008-01-10

Suppression of Oral HHV8 Shedding With Valganciclovir

University of Washington

Phase 2 Completed
32 enrolled
Sarcoma

Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon ⚡